NO20023527L - Pyrido(2,3-d)pyrimidin-2,7-diamin kinaseinhibitorer - Google Patents

Pyrido(2,3-d)pyrimidin-2,7-diamin kinaseinhibitorer

Info

Publication number
NO20023527L
NO20023527L NO20023527A NO20023527A NO20023527L NO 20023527 L NO20023527 L NO 20023527L NO 20023527 A NO20023527 A NO 20023527A NO 20023527 A NO20023527 A NO 20023527A NO 20023527 L NO20023527 L NO 20023527L
Authority
NO
Norway
Prior art keywords
pyrido
pyrimidine
diamine
kinase inhibitors
kinase
Prior art date
Application number
NO20023527A
Other languages
English (en)
Other versions
NO20023527D0 (no
Inventor
Richard John Booth
Ellen Myra Dobrusin
Vara Prasad Venkata
Dennis Joseph Mcnamara
Peter Laurence Toogood
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20023527D0 publication Critical patent/NO20023527D0/no
Publication of NO20023527L publication Critical patent/NO20023527L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
NO20023527A 2000-01-25 2002-07-24 Pyrido(2,3-d)pyrimidin-2,7-diamin kinaseinhibitorer NO20023527L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17826100P 2000-01-25 2000-01-25
PCT/IB2001/000069 WO2001055147A1 (en) 2000-01-25 2001-01-23 PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS

Publications (2)

Publication Number Publication Date
NO20023527D0 NO20023527D0 (no) 2002-07-24
NO20023527L true NO20023527L (no) 2002-09-10

Family

ID=22651853

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023527A NO20023527L (no) 2000-01-25 2002-07-24 Pyrido(2,3-d)pyrimidin-2,7-diamin kinaseinhibitorer

Country Status (34)

Country Link
EP (1) EP1254137A1 (no)
JP (1) JP4047010B2 (no)
KR (1) KR20020065939A (no)
CN (1) CN1395578A (no)
AP (1) AP2002002586A0 (no)
AR (1) AR030044A1 (no)
AU (1) AU2542501A (no)
BG (1) BG106850A (no)
BR (1) BR0107751A (no)
CA (1) CA2397961C (no)
CO (1) CO5261549A1 (no)
CR (1) CR6706A (no)
CZ (1) CZ20022475A3 (no)
DZ (1) DZ3266A1 (no)
EA (1) EA200200643A1 (no)
EE (1) EE200200405A (no)
GT (1) GT200100016A (no)
HN (1) HN2001000013A (no)
HU (1) HUP0204141A3 (no)
IL (1) IL150545A0 (no)
IS (1) IS6443A (no)
MA (1) MA26868A1 (no)
MX (1) MXPA02007221A (no)
NO (1) NO20023527L (no)
OA (1) OA12161A (no)
PA (1) PA8510701A1 (no)
PE (1) PE20011066A1 (no)
PL (1) PL356802A1 (no)
SK (1) SK10632002A3 (no)
SV (1) SV2002000294A (no)
TN (1) TNSN01014A1 (no)
WO (1) WO2001055147A1 (no)
YU (1) YU50402A (no)
ZA (1) ZA200205879B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
MXPA03003612A (es) 2000-10-23 2003-06-19 Smithkline Beecham Corp Compuestos novedosos.
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
BR0309053A (pt) 2002-04-19 2005-02-22 Smithkline Beecham Corp Compostos
WO2004048343A1 (en) * 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
TW200502236A (en) 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
CN101014600A (zh) * 2004-09-21 2007-08-08 霍夫曼-拉罗奇有限公司 用作蛋白激酶抑制剂的6-(2-烷基-苯基)-吡啶并[2,3-d]嘧啶类
AR053450A1 (es) 2005-03-25 2007-05-09 Glaxo Group Ltd Derivados de 3,4-dihidro-pirimido(4,5-d)pirimidin-2-(1h)-ona 1,5,7 trisustituidos como inhibidores de la quinasa p38
US7423042B2 (en) 2005-03-25 2008-09-09 Glaxo Group Limited Compounds
PE20100737A1 (es) 2005-03-25 2010-11-27 Glaxo Group Ltd Nuevos compuestos
CN101495475A (zh) 2005-03-25 2009-07-29 葛兰素集团有限公司 制备吡啶并[2,3-d]嘧啶-7-酮和3,4-二氢嘧啶并[4,5-d]嘧啶-2(1H)-酮衍生物的方法
FR2887882B1 (fr) 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
KR100962723B1 (ko) * 2005-07-21 2010-06-09 에프. 호프만-라 로슈 아게 단백질 티로신 포스파타제1b 억제제로서의피리도[2,3-d]피리미딘-2,4-다이아민 화합물
ES2351939T3 (es) 2005-08-09 2011-02-14 Irm Llc Compuestos y composiciones como inhibidores de proteínas cinasas.
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
FR2910813B1 (fr) * 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
MX2011005720A (es) * 2008-12-01 2011-06-17 Merck Patent Gmbh Pirido [4,3-d] pirimidinas 2,5-diamino sustituidas como inhibidores de autotaxina contra cancer.
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
WO2014151682A1 (en) * 2013-03-14 2014-09-25 Icahn School Of Medicine At Mount Sinai Pyrimidine compounds as kinase inhibitors
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR101671404B1 (ko) * 2014-09-02 2016-11-02 한국원자력의학원 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
CN107286180B (zh) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20012444B (en) * 1994-11-14 2001-05-25 Warner Lambert Company Us 6-Aryl Pyrido[2,3-d]Pyrimidines and Naphthyridines, Pharmaceutical Composition on Their Basis and Application for Inhibiting Cellular Proliferation
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
ES2310039T3 (es) * 1998-05-26 2008-12-16 Warner-Lambert Company Llc Pirimidinas biciclicas y 3,4-dihidropirimidinas biciclicas como inhibidores de la proliferacion celular.

Also Published As

Publication number Publication date
PL356802A1 (en) 2004-07-12
IS6443A (is) 2002-06-25
WO2001055147A1 (en) 2001-08-02
CA2397961A1 (en) 2001-08-02
TNSN01014A1 (fr) 2005-11-10
CO5261549A1 (es) 2003-03-31
DZ3266A1 (fr) 2001-08-02
EE200200405A (et) 2003-12-15
ZA200205879B (en) 2003-09-29
MXPA02007221A (es) 2002-11-29
KR20020065939A (ko) 2002-08-14
PE20011066A1 (es) 2001-10-22
IL150545A0 (en) 2003-02-12
AP2002002586A0 (en) 2002-09-30
HUP0204141A3 (en) 2005-03-29
HUP0204141A2 (hu) 2003-04-28
GT200100016A (es) 2001-10-19
MA26868A1 (fr) 2004-12-20
JP4047010B2 (ja) 2008-02-13
AU2542501A (en) 2001-08-07
CR6706A (es) 2005-04-04
SV2002000294A (es) 2002-07-16
OA12161A (en) 2006-05-08
BR0107751A (pt) 2002-11-12
PA8510701A1 (es) 2002-12-11
YU50402A (sh) 2005-11-28
EP1254137A1 (en) 2002-11-06
CN1395578A (zh) 2003-02-05
BG106850A (bg) 2003-02-28
NO20023527D0 (no) 2002-07-24
EA200200643A1 (ru) 2002-12-26
SK10632002A3 (sk) 2003-06-03
AR030044A1 (es) 2003-08-13
CZ20022475A3 (cs) 2003-03-12
JP2003523357A (ja) 2003-08-05
CA2397961C (en) 2008-08-26
HN2001000013A (es) 2001-06-18

Similar Documents

Publication Publication Date Title
NO20023527D0 (no) Pyrido(2,3-d)pyrimidin-2,7-diamin kinaseinhibitorer
NO20024235L (no) 5-alkylpyrido(2,3-D)pyrimidin tyrosin kinase inhibitorer
ATE309245T1 (de) 5-amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3- d)pyrimidin-derivate
PT1235830E (pt) Compostos de pirrolo¬2,3-d|pirimidina como inibidores das proteina cinases
ATE387446T1 (de) Pyrido(2,3-d)pyrimidin-2,4-diamine als pde-2- inhibitoren
ATE388713T1 (de) 4-amino-6-phenyl-pyrrolo(2,3-d)pyrimidin derivate
ATE284404T1 (de) Pyrazolo(4,3-d)pyrimidinderivate
ATE372988T1 (de) Pyrimidin-derivate
ATE231866T1 (de) Pyrazolo(4, 3-d)pyrimidine
NO995036D0 (no) 5,7-disubstituerte 4-aminopyrido[2,3-d]pyrimidinforbindelser og deres anvendelse som adenosinkinaseinhibitorer
ATE276260T1 (de) 2-aminoalkyl-thieno(2,3-d)pyrimidine
ATE297927T1 (de) Substituierte 3,4-dihydro-pyrido(1,2-a)pyrimidine
DK1326866T3 (da) Substituerede 3,4-dihydro-pyrido[1,2-a]pyrimidiner

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application